Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 August 2021 | Story Ruan Bruwer
Louzanne Coetzee at the Paralympics in Tokyo with her two guides, Claus Kempen (left) and Estean Badenhorst. She is one of 34 members in Team South Africa.

For some athletes, the postponement of the Paralympics was a big frustration, but for Louzanne Coetzee it was a ‘blessing in disguise’.

According to the former University of the Free State (UFS) student and current Residence Head of Akasia on the UFS Bloemfontein Campus, she was more than happy to get another 12 months to prepare herself to the very best of her ability. She will be in action at the Tokyo Paralympics in the 1 500 m on Sunday (29 August 2021) and Monday (30 August). On 5 September, she will tackle the marathon. It is her second Paralympics. 

“This is the most exited I have ever been for an event. It has been so long since I was able to compete on a high level. I think it is a blessing in disguise. It allowed me more time to prepare. I’m in a great state and I cannot wait,” she said.

In the 1 500 m, Coetzee will be guided by Estean Badenhorst. In the marathon she will run next to Claus Kempen, with whom she has completed a couple of marathons before.
“They are both very experienced and I’m fortunate to have such a great team with me. When you are running an event like the 1 500 m, you need to fully trust your guide with his decision making.”

“The main focus is the track item. I won’t put too much pressure on myself in the marathon. The prime goal is to gain experience in the longer distance, because that is where I’ll be shifting in the future,” she explained.

The South African 1 500 m record holder in the T11 classification (totally blind) clocked a personal best time of 4:51.65 in 2019. She is the world record holder in the 5 000 m; however, the item does not feature on the Paralympic programme. 

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept